Please anonymize the following text: 



Record date: 2098-02-12


RENAL CONSULT NOTE 
 

ATTENDING &#8211; Dr. John Ingle
DOA &#8211; 02/12/98

Consult indication - Pt with ESRD, consulted for HD needs
 from ED department


HPI - 

64 yo F with ho ESRD due to DM on HD TTS, Type 2 DM, CVA, prior GI bleeds -&gt; admitted with nausea and vomiting and abdo distention.
Very difficult history in ED as limited English and orevious dysphasia from CVA.


Recently admitted 12/1-12/10/97 for N/V/abd pain.  CT abdomen demonstrated thickened sigmoid colon/rectum.  Underwent colonoscopy demonstrating polyp -&gt; high grade dysplasia/adenoca on path.  CT pancreas protocol demonstrated low density foci in the head and uncinate process unchanged since 1/96.  Had blood cx positive for stenotrophomonas (cefepime resistant), e faecium, and achromobacter, briefly received cefepime, surveillance cx&#8217;s negative, and abx were d/c&#8217;ed.
 





PMH - 

1. ESRD since 2096

- etiology presumed DM

- access = L brachiocephalic AVF 

2. Chronic decubitus ulcers

3. Type II DM

4. Prior GI bleeding

- no prior endoscopy report from MH

5. CVA 12/96, previous PEG tube now removed

6. Cataracts

7. Hypertension 
8. Past TTE 7/97

Mild AI, TR, PI, LVSF 68, R PA dilation, RV no diln/hypokinesis

9. Stage I-II colon cancer 



Medications (from last discharge):


Heparin 5000 UNITS SC TIDAlbuterol Nebulizer 2.5 MG NEB Q6H prnCalcium Acetate ( 1 Gelcap=667 Mg) 667 MG PO TIDCholestyramine Resin Dried 4 GM PO BIDLisinopril 40 MG PO QDNephrocaps 1 CAPSULE PO QDOmeprazole 40 MG PO BIDOndansetron Hcl (Non Chemo) (Zofran (Non Chemo) ) 4 MG IV Q8H prnAcetaminophen (Tylenol  ) 650 MG PO Q6H prnInsulin Regular Inj  SC AC (Sliding Scale)Labetalol Hcl 300 MG PO TIDAcetylsalicylic Acid (Aspirin ) 81 MG PO QDInsulin Glargine (Lantus ) 5 UNITS SC QHSAmlodipine 10 MG PO QPMHydralazine Hcl 10 MG PO QID prn    



Allergies:

NKDA


FH/SH - 

Lives in nursing facility

No alcohol, no illicitr
Daughter lives nearby



EXAM:
BP  193/69   HR  62  T  98F
Hands: no clubbing
H+N: no elevated JVP, erythema and injection elft eye? conjunctivitis, no nodes
CVS: normal S1 and S2, no added.murmurs/rubs heard
Chest: dull right abse, creps bibasally
Abdo: SNT, distended, BS present
Legs: no odema, Calves soft


LABS:
Results02/12/2098 NA 139,  K 6.2 (H),  CL 94 (L),  CO2 29.2,  BUN 37 (H),  CRE 3.47 (H)02/12/2098 NA 135,  K 6.6 (H),  CL 93 (L),  CO2 26.1,  BUN 38 (H),  CRE 3.56 (H)02/12/2098 CA 10.102/12/2098 CA 9.9,  ALB 4.2,  LIPS 2202/12/2098 aPO2 96,  aPCO2 52 (H),  aPH 7.40,  K-PL 5.2 (H)02/12/2098 ALT/SGPT 32 (H),  AST/SGOT 87 (H),  ALKP 233 (H),  TBILI 0.502/12/2098 WBC 9.6,  HGB 13.7,  PLT 29702/12/2098 PT-INR 1.2


A/PLAN:
Nausea+Vomiting
Concerning in light of history of colon ca, but did not appear to have large intraluminal lesion from what I can see.
Note plan for CT tonight per ED management


ESKD
K from ABG was 5.2
No immediate need to dialyse tonight
Will schedule for HD first shift tomorrow
Treat K medically overnight as needed; please limit IV fluids


Anaemia
Hb above target, hold EPO for now


Bone
Please check phosphate and iPTH
Will dose adjust binders and Vit based on results


HTN
Need to assess complaince with meds
Consider prn iv labetalol as needed for severe HTN
Perhaps add nitrate if needed for longer-term management 


Pleural effusions
Consider tapping if not done recently in light of malignancy in history


Calvin Stanley Tripp
Renal Fellow
#94122




Renal Staff Addendum


Patient seen and examined on dialysis. Case discussed with Fellow. Note appreciated.


- presents with nausea and vomiting
- abd CT shows:
       increasing size colonic neoplasm
       right sided colitis
       markedly distended bladder
- BP poorly controlled
- Hyperkalemia
- Hypoglycemia


REC
1. Dialysis 3hrs 2K 2.5Ca
2. UF 2L
3. AVG access
4. Epogen and Zemplar pre outpatient regimen
5. Straight cath bladder and send off urine culture: Retention of urine and UTI might explain her prsentation
6. Surgical f/u re colon neoplasm: she is a high risk surgical candidate
7. D10W IV while NPO; RISS
8. Resume po BP meds. (no hold on dialysis days)




John Ingle MD.






Case Summary
Patient with ESRD with a history of colon cancer and DM. She is admitted to the hospital with nausea and vomiting and abdominal pain. She also presents with a history of hypertension, type 2 diabetes, and a history of colon cancer.
On admission, there were no abnormal findings on the physical examination.
The lab studies showed a H+ 6.2, K + 6.2, CRE +.9, BUN +.04, Cr+3.47, aPO2 96, aPCO2 52, aPH 7.4, PLT +.22, WBC +.32, HGB +13.7, PLT +2.3, and PT INR+.12.
The abdomen ultrasound demonstrated increased size colonic neoplasm, right side colitis, and distended bladder.
The CT abdomen showed thickening sigmoid colon/rectum, low density foci in the head and uncinate process, and low density foci in the pancreas unchanged since 1/196.
The patient received cefepime, surveillance cx’s were negative, and abx were d/c’ed at this point. She was given a 2L UF, AVG access, EPO, and epogen and Zemplar were pre outpatient regimen.
The patient was placed on DDHD and the renal staff was notified by Dr. 
Ingle. The next day, the hemodialysis (D1H) was initiated and 2K of IV K +. The patient is now stable.




















The renal staff has added the following orders: 

Dialysis 3hrs.

UF 2L
AVG access
Epogen 4000 units
Zemplar 3240 units
Renal staff has added: Dialysis 3hrs
UF 2L
AVG access
Epogen 400 units
Zemplar 32 units 2H2H22 40H22






1H:1




Zplatla 00





10H22




H2H- H

20
20


Patient 2








2H-H2











1






Pat
20



2



H


2

 201

20

2

2
2 HIV
220
H









 
2 2
2
2
20
   
H
 

2 H  

H2
2
20-2 HIV
1

11- 0
2
  







20 &AT H


2:  20

1
20



2 H


1

 









1
   






 20
H





1
 





20


2
2




  



 

R





RR 










 

 A.
 

A, and/date 3, and/ and  and  date and 
:  &  (1: A
20  &  and 
:M.
. RICING  &: : 20231 2: CAP:
. An: &:  : &:
:
 (1. 120 (0: 2131: 1:
 - A, 6 (06342977: 121: & and (.A (1: A - An &: An.  &09.1 An:A An:8, An. A (ARO. An An, An:010 &, CRA in. & (1 An &. An & &, An & &,2 -3,  in April in An An  (2 An, the: -  and, A -2, and and a with  and ( and. A and  and and &: and, a in ( &. A. A,10- 1 An (9 An, An C An and a  and ( An and a and a, the Anistic-2 and Anistic:1 1 and and:  (  &  &, a,  An. An2 An ( An An1 An An An An Col An An and, An and, An and and:  a and for and, patient & and [ & 00. An An & Anist Anish. An Anified to,  and  &1 An An An An and.. Anist Anish An ( B. -  and - and & the, C and and, anics, the and -, Mager-2 An, - &., the and,  and,  An. & &  in (  with - An with the & ( and in a with &  -  - - → - & –  ( &,. &.-2 & -.:,. in:  in, & 1 &. - &-  and-2 and. -1 Anist Anish.- : an: An: :  M &:: M An An Anish An:: - An in:: ( - ( An  -  ( and and ( [ - [ [ in in:  in: –  ( -: and [ and for and – in - for for and, for in for, in, -: &, ( - ( for - An in in -- and and- P An C C and  - An: M and:  -  for to a - for to and- to --  - [- M and, -. - [0   - [000 --1 - - and – and - to  I  for  - A - A- A for - - and,, M and - C M for and - - to to and – for ( with- - - for for -- for - -  for in for -2-  and –-0,  and.,  (- & ( -  and - /-  -  & – M –, ( and,  and, - H P – – – & — –, – -, and - ( ( ( --  - - ( C- - - - - and, - -- and –- -, -  - - - –,  M A –- PO -, M- (. –,. - - -- M- and -- – -- H and- for and and- -... (-  C- H -- R.  H  H. C P - and –-0 --0 - –, ( -   ( and- C H- M.-0 H P C R – - - – - ( H A H C.-1- M H- C R L C H H -  H P C- - P - R M C M -  - –-. ( - ( H  - - :. C ( C - - C - - C - H - A C (- I ( C ( C - C H C H C: I- C - H A C H C C C R ( - H C C R M C R I  R M H - R M – ( C ( - - P - C - - C - ( C A C - C –  C R ( C ( of - ( C - C R – C  C - P - ( M I C P  ( P.  M- M H - P - C. -0 I L I R I (  R - R ( H ( ( R, L, 0 (, L0. F - I P  - C P L H L H R - H,  - H ( H H- C (   ( - L and and O C Cger H - H  C ( -, H - C – and ( - and (.. F0 C. F - ( H C. C - - ( F ( ( C C- C P. ( ( C L H P H. H- ( H,  - ( C  ( H -..  and  (, C I M ( H  H, [- H C ( H H, ( P - - - - H C C M ( H ( ( H- M - ( R M- and and. - and  - P. ( C C and P - M H (. ( ( ( C ( F C R. (.  ( ( H ( H F-. M. C M H -- H ( A (- M ( C H C ( M P. (, ( A- U C A H- M ( C ( C T- A N- Al, C - C H- - (-  M- M C M- (- H ( C  M M ( C C ( ( I C C- M C C M. A M C ( - and and ( (- I M ( (- M ( C –- C U- A - F ( - I T- H C U I H M T- P, C  I U ( M U M ( ( M- M. M- M - H M F H F-, Al- C I - I,  ( MD- - M M M  M M ( I H - M M U C C  M- M, M M C MM,- M M M M M M M M M M M M M and M M - M M M M M M M. - M M 